These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31407410)

  • 1. Nicotinamide increases the sensitivity of chronic myeloid leukemia cells to doxorubicin via the inhibition of SIRT1.
    Pan S; Leng J; Deng X; Ruan H; Zhou L; Jamal M; Xiao R; Xiong J; Yin Q; Wu Y; Wang M; Yuan W; Shao L; Zhang Q
    J Cell Biochem; 2020 Jan; 121(1):574-586. PubMed ID: 31407410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
    Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways.
    Zhang JG; Zhao G; Qin Q; Wang B; Liu L; Liu Y; Deng SC; Tian K; Wang CY
    Pancreatology; 2013; 13(2):140-6. PubMed ID: 23561972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRT1 inhibition impairs non-homologous end joining DNA damage repair by increasing Ku70 acetylation in chronic myeloid leukemia cells.
    Zhang W; Wu H; Yang M; Ye S; Li L; Zhang H; Hu J; Wang X; Xu J; Liang A
    Oncotarget; 2016 Mar; 7(12):13538-50. PubMed ID: 26646449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinamide Overcomes Doxorubicin Resistance of Breast Cancer Cells through Deregulating SIRT1/Akt Pathway.
    Wei Y; Guo Y; Zhou J; Dai K; Xu Q; Jin X
    Anticancer Agents Med Chem; 2019; 19(5):687-696. PubMed ID: 30648523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of apoptosis induced by SIRT1 deacetylase inhibitors in human breast cancer MCF-7 drug-resistant cells].
    Li Y; Xu R; Zhang XM; Li DD; He QY
    Yao Xue Xue Bao; 2008 Oct; 43(10):1003-10. PubMed ID: 19127863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hyaluronic acid formation sensitizes chronic myelogenous leukemia to treatment with doxorubicin.
    Uchakina ON; Ban H; Hostetler BJ; McKallip RJ
    Glycobiology; 2016 Nov; 26(11):1171-1179. PubMed ID: 27261196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotinamide ameliorates palmitate-induced ER stress in hepatocytes via cAMP/PKA/CREB pathway-dependent Sirt1 upregulation.
    Li J; Dou X; Li S; Zhang X; Zeng Y; Song Z
    Biochim Biophys Acta; 2015 Nov; 1853(11 Pt A):2929-36. PubMed ID: 26352206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells.
    Hwang ES; Song SB
    Cell Mol Life Sci; 2017 Sep; 74(18):3347-3362. PubMed ID: 28417163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
    Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
    Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.
    Audrito V; Vaisitti T; Rossi D; Gottardi D; D'Arena G; Laurenti L; Gaidano G; Malavasi F; Deaglio S
    Cancer Res; 2011 Jul; 71(13):4473-83. PubMed ID: 21565980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition.
    Wei D; Lu T; Ma D; Yu K; Zhang T; Xiong J; Wang W; Zhang Z; Fang Q; Wang J
    Life Sci; 2018 Oct; 211():224-237. PubMed ID: 30248347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells.
    Li L; Bhatia R
    Curr Opin Hematol; 2015 Jul; 22(4):324-9. PubMed ID: 26049753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1.
    Wang Z; Chen CC; Chen W
    Stem Cells; 2015 Dec; 33(12):3437-51. PubMed ID: 26466808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
    Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment.
    Peled T; Shoham H; Aschengrau D; Yackoubov D; Frei G; Rosenheimer G N; Lerrer B; Cohen HY; Nagler A; Fibach E; Peled A
    Exp Hematol; 2012 Apr; 40(4):342-55.e1. PubMed ID: 22198152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirtuin 1 alleviates endoplasmic reticulum stress-mediated apoptosis of intestinal epithelial cells in ulcerative colitis.
    Ren MT; Gu ML; Zhou XX; Yu MS; Pan HH; Ji F; Ding CY
    World J Gastroenterol; 2019 Oct; 25(38):5800-5813. PubMed ID: 31636473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.
    Yang X; Pang J; Shen N; Yan F; Wu LC; Al-Kali A; Litzow MR; Peng Y; Lee RJ; Liu S
    Oncotarget; 2016 Jun; 7(24):36382-36394. PubMed ID: 27144331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.